PRAC meeting highlights 8-11 January 2024

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines.

The current PRAC highlights from the January 2024 meeting provides further information on the potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines and outlines precautionary measures for use.